TransMedics Group, Inc. (TMDX)
Warm-perfusion organ preservation and an increasingly integrated transplant logistics platform — differentiated technology, but 2026 reads as an execution-and-proof year ahead of larger 2027 catalysts.
"Report Price" is the market price valid when this analysis was written — the entire thesis, valuation, and model are anchored to that price. The live price (courtesy of Yahoo Finance, may be delayed 15–20 minutes) is shown for reference only and will move over time.
Get the Full PDF: Report + Financial Model
Enter your email to unlock the complete TMDX writeup — every debate question, the full income statement, balance sheet, cash flow, DCF sensitivity table, and comps analysis, in one PDF.
| Company | TransMedics | Ticker | TMDX |
| Market Price | $72.91 | Market Cap | $2.52B |
| Average Volume | 1.70M | Beta | 1.91 |
| 52-Week Range | $60.11 – $156.00 | Shares Outstanding | 34.56M |
| Market Date | 7/12/26 | NTM P/E | 31.9x |
| Analyst | Bryant B. | Model Support | 3-Statement Model, DCF, Comps |
Decision
Hold; potential buy if you believe in near-term growth and execution.
Why Now
Base-model valuation implies upside, but 2026 is more of an execution-and-proof year, while larger thesis-changing catalysts still appear weighted toward 2027.
What Would Make It Interesting
Cleaner execution, improving margins, or a 30–40% dislocation.
Executive Summary
TransMedics (TMDX) combines a unique, differentiated medtech platform with a strong integrated service model (transportation + logistics + all-in-one transplant stack), but it faces meaningful execution challenges as it scales, along with regulatory concerns over the near- to mid-term horizon. Despite the roughly 50% correction since March, and with the base model implying a value of about $96.84 versus the current price of roughly $73, this remains a HOLD / WATCHLIST name given the continued unknowns ahead: execution risk, expected margin compression, growth normalization, and a setup where 2026 is primarily an execution-and-proof year while the larger thesis-changing catalysts appear more heavily weighted to 2027.
Why It Matters
Differentiated medtech platform with a tightly integrated logistics and service model.
What Is Working
Unique market position, meaningful transplant workflow integration, and long-run adoption potential.
What Is Holding It Back
Execution risk, margin pressure, growth normalization, and limited near-term catalysts.
Company Description & Business Model
TransMedics is a SMID-cap medical device company focused on organ transplant therapy for end-stage organ failure patients. Its OCS (Organ Care System) technology replicates the organ's natural living, functioning environment outside the human body, extending viable transport time versus traditional cold-storage practices. Through its National OCS Program (NOP), the company also coordinates transplant logistics directly — it owns 22 aircraft (primarily Embraer Phenom 300 jets) to support high transplant-mission throughput.
Revenue is tied to transplant procedure volume rather than one-time equipment sales. Hospitals pay per case across: the OCS disposable/perfusion set plus device usage, and — if using the full program — the NOP service fee, which bundles the TransMedics surgical team, clinical monitoring, logistics coordination, and air/ground transportation. Typical transplant economics run ~$38K–$80K per heart transplant (occasionally over $100K), and roughly $107K–$120K per liver transplant in certain cases.
Margin structure: disposable perfusion sets are high-margin, recurring, and proprietary; logistics (aircraft, staffing, fuel) and NOP service expansion are lower-margin. As the National OCS Program grows as a share of the business, that mix shift likely compresses overall margins — the central tension in the thesis.
~40K U.S. transplants occur annually. At ~5,200 cases, TMDX holds roughly 13% penetration. Company target: 10,000 cases (~25% penetration) by 2028.
Liver ~80–81% of revenue and the largest growth driver; Heart ~17–18%; Lung ~1–2%. Single reported segment: Organ Transplant Technology & Services (~99% of revenue).
Top-line growth has decelerated meaningfully: 2023 +158.5% → 2024 +82.7% → 2025 +37.1%. Normalization is a central debate.
Core Thesis & Variant Perception
- Differentiated platform: warm-perfusion leadership across heart, liver, and lung with recurring disposables and workflow integration.
- Service model debate: the company increasingly sells a full-stack transplant solution, deepening customer dependence but increasing operating complexity.
- Core investment question: can TransMedics scale while protecting margins and returns on capital?
Variant perception: the market appears to be shifting its view of TMDX from premium medtech toward a more logistics-heavy healthcare-services model. The opportunity is that investors may be over-discounting temporary execution issues; the risk is that the model is structurally more complex and lower-multiple than first assumed.
Valuation framing: base-model value sits above the current share price, creating upside on paper — but the stock still lacks urgency given execution risk, margin uncertainty, and the need for stronger confidence in scalability. The bull case requires better penetration, margin recovery, and renewed confidence in scalability; the bear case remains meaningful if execution or margins worsen.
Bull / Base / Bear
Bull Case
Penetration expands materially, margins recover into the low-60% gross-margin range, and the market regains confidence in long-duration growth and scalability. Implies a move toward roughly $148/share if penetration reaches ~24–25% of the U.S. market, gross margin reaches ~62–63%, and the market re-rates to ~20x+ EBITDA.
Base Case
The stock appears undervalued relative to the base model, but growth continues to normalize, margin recovery is gradual, and the next major catalyst set still sits in 2027. Base model implies ~$96.84/share, roughly 30% upside from current levels.
Bear Case
Execution remains uneven, logistics costs stay elevated, and margins fail to recover, driving a lower-multiple healthcare-services framing and further downside. If penetration stalls and gross margin remains near 58%, implied value falls to roughly $43–55/share.
Key Risks
- Service and logistics intensity may dilute the economics of the device platform.
- Margin recovery could take longer than expected.
- Operational missteps have outsized consequences in a time-sensitive transplant model.
- Short interest (~22–23% of float) can continue to amplify volatility.
- Organ donor supply must expand to sustain long-term growth.
- Reimbursement changes, especially involving Medicare, could reduce demand.
- Geographic concentration remains high — the U.S. is still the primary market despite European expansion.
- Technology risk persists if a competitor develops an equally effective multi-organ system without the same logistics burden.
Key Monitoring Points (Next 2–3 Quarters)
- Gross-margin stabilization versus further deterioration.
- NOP efficiency and evidence of improving logistics productivity.
- Fleet utilization and whether double-shifting improves operating leverage.
- Guidance credibility and quarter-to-quarter execution consistency.
- Early signs that Europe can contribute to growth without worsening the cost profile.
What Would Change the View
- More constructive if: margins stabilize, utilization improves, and guidance credibility returns.
- More aggressive if: the model proves it can scale with stronger incremental economics.
- More cautious if: gross margin deteriorates further or NOP economics remain weak.
Key Questions & Debate Areas
1. Why has the stock declined ~52% from its high, and is the ~22–23% short interest improving?
The sell-off since early March reflects several compounding factors: an already-premium multiple with elevated Street EPS expectations, broad macro weakness, insider selling in early March filings, and then a Q1 earnings miss — EPS of $0.30 versus consensus of $0.62 (~50% miss), gross margin falling to 58% from 61%, and OpEx rising ~45% YoY despite 21% revenue growth. The market is increasingly valuing TMDX more like an operationally heavy logistics platform than a pure high-margin medtech story. Short interest has eased modestly, from ~26% in May to ~22–23% in June 2026, but the short thesis — rapid OpEx growth, logistics cost inflation, continuing margin deterioration — remains intact.
2. Is the ~170% headline debt-to-equity ratio a real problem?
The headline ratio is misleading because the debt stack mixes very different obligations: $453.5M in convertible notes at 1.5% (maturing 2028), ~$60M in loans, and a $344M finance lease tied to a headquarters relocation that doesn't behave like conventional refinanceable debt. Excluding the lease, a more representative debt-to-equity ratio is closer to 1.04x, and on a net-debt basis the picture is comfortable given ~$462M of cash and trailing free cash flow of ~$121M. No near-term equity raise appears likely; late 2027–2028 could present refinancing risk if cash needs rise.
3. Can margin pressure resolve within 3–5 years, and can the stock double?
Possibly, but a great deal must go right. Management targets ~60% gross margin and ~30% operating margin by 2028; the base case here reaches ~60% gross margin and ~25%+ EBIT margin by 2030 via fleet utilization gains, NOP scale, and operating leverage. A move from ~$74 to ~$148 requires the full bull case: penetration to ~24–25%, gross margin to ~62–63%, and a re-rating to ~20x+ EBITDA on re-accelerating growth — achievable if ENHANCE/DENOVO adoption and European NOP expansion deliver, but this is the upside case, not the base case.
4. How important is the European pipeline and air-fleet utilization?
Pipeline: next-generation OCS Heart (ENHANCE, full FDA IDE approval Feb. 2026, ~650-patient trial) and Lung (DENOVO, Jan. 2026) trials are enrolling to expand the addressable donor pool. Europe: a definitive agreement to invest in Germany's PAD Aviation (closing late 2026), an Italy NOP build-out (up to four hubs), and a Mercedes-Benz V-Class ground fleet — management frames Europe as potentially doubling the addressable market, though pricing and execution still require validation. U.S. aviation: management is pivoting from fleet expansion toward higher utilization via double-shifting 20–30% of planes; Q1 2026 air-mission coverage reached 82% versus 78% previously.
5. What margin of safety is appropriate?
Given evolving margins, high capital intensity, meaningful execution risk, and elevated short interest, a discount of roughly 30–40% to fair value is appropriate. Under that framework, the long-term base-case buy zone is roughly $68. The current price sits below the base-model implied value, but the layered risk profile still argues for patience before treating this as an active buy rather than a watchlist name.
Financial Highlights
Condensed from the full 3-statement model. All figures in $000s except per-share data.
| ($000s) | FY23A | FY24A | FY25A | FY26F | FY27F | FY28F | FY29F | FY30F |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 241,623 | 441,540 | 605,494 | 742,702 | 879,977 | 1,017,284 | 1,152,665 | 1,301,003 |
| Gross Profit | 154,093 | 262,081 | 362,806 | 431,510 | 519,187 | 610,370 | 691,599 | 780,602 |
| Gross Margin % | 63.8% | 59.4% | 59.9% | 58.1% | 59.0% | 60.0% | 60.0% | 60.0% |
| EBIT | (28,727) | 37,496 | 108,583 | 86,153 | 140,796 | 233,975 | 276,640 | 325,251 |
| EBITDA | (20,550) | 57,254 | 135,768 | 119,575 | 178,635 | 276,701 | 322,746 | 377,291 |
| Net Income | (25,028) | 35,464 | 190,291 | 69,435 | 114,314 | 190,932 | 230,057 | 274,849 |
| Diluted EPS | ($0.77) | $1.01 | $4.69 | $1.69 | $2.74 | $4.50 | $5.35 | $6.29 |
CapEx structurally elevated (~$57M TTM, ~8–10% of revenue) given owned OCS console and aviation fleet; expected to ease toward ~7% as utilization improves. SBC runs ~6% of revenue (~$37M), expected to scale down as a % of revenue through the forecast.
~$462M cash, ~$857M total debt (mostly a $453.5M 1.5% convertible note and a $344M finance lease). Net debt/EBITDA turns negative (net cash) from FY26F onward under the model.
ROIC improves from ~12.4% (FY26F) to ~33.9% (FY30F) in the base case as margins recover and capital intensity eases — a key swing factor in the bull case.
Change the Assumptions. See the Value Move.
A simplified DCF-and-comps triangulation, structured the same way the report is (DCF, EV/Sales, EV/EBITDA, P/E, weighted). Adjust revenue growth, terminal operating margin, WACC, and the exit multiple to see your own implied price — this isn't the full 11-tab model, but a stripped-down version for exploring assumption sensitivity.
Historical revenue (lighter) vs. projected (blue) under your assumptions. All figures in $000s.
Simplified for educational purposes — not investment advice. Does not reproduce every line of the full model.
Want the Full 3-Statement Model?
The full PDF includes the quarterly income statement, complete cash flow statement, balance sheet, per-case revenue build, DCF sensitivity table, and full comps analysis — everything that doesn't fit on this page.
Valuation — DCF, Comps & Triangulation
Two DCF methods (perpetuity growth and exit multiple) are blended with comparable-company multiples (EV/Revenue, EV/EBITDA, P/E on CY2027E) to triangulate a single fair-value estimate, weighted toward the metric least distorted by TMDX's current earnings volatility.
| Method | Multiple | $/Share | Weight | Weighted |
|---|---|---|---|---|
| DCF — Average (intrinsic) | — | $88.15 | 15% | $13.22 |
| EV/Sales — Base (lead metric) | 4.0x | $102.53 | 45% | $46.14 |
| EV/EBITDA — justified | 18.0x | $93.60 | 25% | $23.40 |
| P/E — justified | 28.0x | $93.87 | 15% | $14.08 |
| Triangulated Fair Value | $96.84 | 100% | $96.84 |
EV/Sales carries the highest weight as the lead relative metric given near-term earnings/FCF distortion; P/E carries the lowest weight as the most distorted metric near-term.
Comparable Companies (CY2027E)
| Company | Ticker | EV/Rev | EV/EBITDA | P/E |
|---|---|---|---|---|
| Intuitive Surgical | ISRG | 18.0x | 48.0x | 62.0x |
| Insulet | PODD | 9.0x | 38.0x | 65.0x |
| DexCom | DXCM | 8.5x | 28.0x | 45.0x |
| Inspire Medical | INSP | 6.5x | 42.0x | 70.0x |
| Penumbra | PEN | 6.0x | 40.0x | 55.0x |
| Globus Medical | GMED | 4.0x | 13.0x | 22.0x |
| TransMedics (subject) | TMDX | 3.4x | 21.4x | 22.2x |
| Median | 7.5x | 39.0x | 58.5x |
Football Field — Implied Value per Share
| Methodology | Low | High |
|---|---|---|
| DCF — Perpetuity Growth | $41.98 | $88.61 |
| DCF — Exit Multiple (16x–20x) | $112.31 | $137.77 |
| Comps — EV/Revenue (IQR) | $157.37 | $228.34 |
| Comps — EV/EBITDA (IQR) | $159.09 | $216.71 |
| Comps — P/E (IQR) | $159.24 | $215.39 |
| 52-Week Trading Range | $60.11 | $156.00 |
Comps ranges sit meaningfully above the DCF anchor — a reminder that relative valuation is pricing in more of the bull case than the intrinsic model currently supports. Current price: $74.29.
Street View
Consensus price target across 17 analysts sits at $122.50 (high $178, low $70) — but that consensus is stale and includes pre-deceleration peak-optimism targets. Among the most recent ratings: Stifel maintained Hold and cut its target to $75 (May 26, 2026); Canaccord Genuity and TD Cowen both maintained Buy with targets of $124 and $120, respectively (May 6, 2026). The Street still sees material upside in aggregate, but the wide target range reflects real debate on execution, margins, and how to value the business post-derating. Our triangulated fair value of $96.84 sits below both the Street consensus and the most bullish targets — a more conservative anchor.
Catalyst Timeline
| Year | Key Milestones |
|---|---|
| 2026 | ENHANCE enrollment; CHOPS rollout; Europe initial hubs |
| 2027 | ENHANCE data; Kidney IDE filing |
| 2028 | 10K case target; scaling phase |
Questions Outstanding
- What does a normalized growth state look like? Growth is slowing into the ~30% range — does it halve again this year?
- How much of growth is tied to hospital-center adoption (limited) versus organ-supply growth (also limited, but more elastic)?
- What is the true contribution margin per case after logistics, aircraft transportation, and clinical-team costs — and how much does it differ by organ?
- With continued GLP-1 adoption, is there a longer-term structural impact on organ transplant demand and supply?
- Any upcoming FDA, Medicare, or CMS policy shifts that could impact this market?
- Could increasing R&D spend on AI, robotics, and PE capital produce better-capitalized, technologically stronger competitors?
- How fast does international expansion actually ramp growth, and how much margin expansion (if any) does it provide?
- Are the overhangs from the Scorpion Capital short report (January 2025) — mismanagement, improper billing, organ-trafficking allegations — fully resolved?
- As the company relies more heavily on double-shifting its 22-aircraft fleet, does that meaningfully increase safety risk?
Last Chance: Take the Full Analysis With You
Save the complete TMDX report and model PDF to read offline or share — includes every debate question, all financial tables, and the full DCF and comps valuation.
Appendix: Reference Materials
Primary sources used to support this report: